Monitoring of endothelial dysfunction in critically ill patients: The role of endothelial progenitor cells

Current Opinion in Critical Care

Volumn 14, Issue 3, 2008, Pages 354-360

  Cribbs, Sushma K ^a   Martin, Greg S ^a   Rojas, Mauricio ^a  

^a Allergy   (United States)

Author keywords

Angiogenesis; Endothelial progenitor cells; Endothelium; Sepsis; Vasculogenesis

Indexed keywords

BIOLOGICAL MARKER;

ANGIOGENESIS; BONE MARROW; CELL CULTURE; CELL FUNCTION; CRITICAL ILLNESS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HEMODYNAMIC MONITORING; HUMAN; MORBIDITY; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; REVASCULARIZATION; REVIEW; SEPSIS; STEM CELL; VASCULAR DISEASE;

CRITICAL ILLNESS; ENDOTHELIUM, VASCULAR; HUMANS; MONITORING, PHYSIOLOGIC; SEPSIS; STEM CELLS;

EID: 43449098521     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e3282fc216d     Document Type: Review

References (62)

1. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275:964-967.
2. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105:71-77.
3. Reyes M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002; 109:337-346.
4. Murohara T, Ikeda H, Duan J, et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 2000; 105:1527-1536.
5. Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000; 97:3422-3427.
6. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85:221-228.
7. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18:3964-3972.
8. Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106:3009-3017.
9. Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355:1222-1232.
10. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355:1199-1209.
11. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355:1210-1221.
12. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-242.
13. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28:108-121.
14. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
15. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
16. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU group for severe sepsis. JAMA 1995; 274:968-974.
17. Finfer S, Bellomo R, Lipman J, et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30:589-596.
18. Padkin A, Goldfrad C, Brady AR, et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003; 31:2332-2338.
19. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34:344-353.
20. Thomas L. The physiological disturbances produced by endotoxins. Annu Rev Physiol 1954; 16:467-490.
21. Thomas L, Zweifach BW, Benacerraf B. Mechanisms in the production of tissue damage and shock by endotoxins. Trans Assoc Am Physicians 1957; 70:54-63.
22. Fujita M, Kuwano K, Kunitake R, et al. Endothelial cell apoptosis in lipopolysaccharide-induced lung injury in mice. Int Arch Allergy Immunol 1998; 117:202-208.
23. Yamada M, Kubo H, Kobayashi S, et al. Bone marrow-derived progenitor cells are important for lung repair after lipopolysaccharide-induced lung injury. J Immunol 2004; 172:1266-1272.
24. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101:3765-3777.
25. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000; 117:1162-1172.
26. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003; 60:26-39.
27. Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003; 16 (1-2):43-47.
28. Miller DL, Welty-Wolf K, Carraway MS, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002; 26:650-658.
29. Zheng X, Li W, Song Y, et al. Nonhematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia. J Thromb Haemost 2007; 5:1394-1400. This article shows how EPCR expressed on endothelium plays a key role in the coagulation pathway during endotoxemia.
30. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
31. Vallet B, Wiel E. Endothelial cell dysfunction and coagulation. Crit Care Med 2001; 29 (7 Suppl):S36-S41.
32. Zhao B, Bowden RA, Stavchansky SA, Bowman PD. Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays. Am J Physiol Cell Physiol 2001; 281:C1587-C1595.
33. Sakr Y, Dubois MJ, De Backer D, et al. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 2004; 32:1825-1831.
34. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5:434-438.
35. Rafat N, Hanusch C, Brinkkoetter PT, et al. Increased circulating endothelial progenitor cells in septic patients: correlation with survival. Crit Care Med 2007; 35:1677-1684. This is one of the first articles to show that circulating EPCs may be valuable markers in predicting outcomes particularly in sepsis patients.
36. Drake TA, Cheng J, Chang A, Taylor FB Jr. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993; 142:1458-1470.
37. Weiler H, Lindner V, Kerlin B, et al. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol 2001; 21:1531-1537.
38. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477 (1-2):349-360.
39. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, et al. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A 1996; 93:10212-10216.
40. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-674.
41. Liu JW, Dunoyer-Geindre S, Serre-Beinier V, et al. Characterization of endothelial-like cells derived from human mesenchymal stem cells. J Thromb Haemost 2007; 5:826-834. This study characterized endothelial cells cultured from MNCs, showing that these endothelial cells were different than those derived fromcord blood. These endothelial cells had a reduced capacity to differentiate into other cell types, making them potentially useful as a therapy.
42. Prater DN, Case J, Ingram DA, Yoder MC. Working hypothesis to redefine endothelial progenitor cells. Leukemia 2007; 21:1141-1149. This is a complete and thorough review on the different cell culture techniques used to define EPCs. In addition, the authors discuss EPC characterization by FACS and the relationship between EPCs and other hematopoietic stem cells.
43. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348:593-600.
44. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104:2752-2760.
45. Dimmeler S, Zeiher AM. Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res 2000; 87:434-439.
46. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95:952-958.
47. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol 2006; 169:338-346.
48. Ben Shoshan J, George J. Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: from experimental models to human trials. Pharmacol Ther 2007; 115:25-36. This review provides a comprehensive list of the latest articles and literature regarding EPCs as a therapeutic modality in cardiovascular disease.
49. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9:702-712.
50. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10:858-864.
51. Jiang M, Wang B, Wang C, et al. Inhibition of hypoxia-inducible factor-1alpha and endothelial progenitor cell differentiation by adenoviral transfer of small interfering RNA in vitro. J Vasc Res 2006; 43:511-521.
52. Kahler CM, Wechselberger J, Hilbe W, et al. Peripheral infusion of rat bone marrow derived endothelial progenitor cells leads to homing in acute lung injury. Respir Res 2007; 8:50. The authors here used bone marrow derived EPCs to test for homing in a rat transplant model of ALI. By peripherally injecting the EPCs, they were able to demonstrate integration into the lung with ALI, suggesting that transplanted EPCs may be important in establishing vascular integrity.
53. Yamada M, Kubo H, Ishizawa K, et al. Increased circulating endothelial progenitor cells in patients with bacterial pneumonia: evidence that bone marrow derived cells contribute to lung repair. Thorax 2005; 60:410-413.
54. Werner N, Junk S, Laufs U, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003; 93:e17-e24.
55. Taniguchi E, Kin M, Torimura T, et al. Endothelial progenitor cell transplantation improves the survival following liver injury in mice. Gastroenterology 2006; 130:521-531.
56. Mutunga M, Fulton B, Bullock R, et al. Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med 2001; 163:195-200.
57. Tsaganos T, Giamarellos-Bourboulis EJ, Kollias S, et al. Kinetics of progenitor hemopoetic stem cells in sepsis: correlation with patients' survival? BMC Infect Dis 2006; 6:142.
58. Burnham EL, Taylor WR, Quyyumi AA, et al. Increased circulating endothelial progenitor cells are associated with survival in acute lung injury. Am J Respir Crit Care Med 2005; 172:854-860.
59. Xu J, Woods CR, Mora AL, et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 2007; 293:L131-L141. This study shows how BMDMSCs prevented the systemic inflammatory response and ALI seen in a murine model of endotoxemia without engrafting in the lung. These observations demonstrated that stem cells may be immunomodulatory, and hence a potential therapeutic option in sepsis.
60. Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179:1855-1863. This study demonstrated for the first time that intrapulmonary administration of BMD MSCs conferred a survival advantage in a mouse model of endotoxin-induced ALI. In addition, there was significant histological improvement in severity of ALI.
61. Mei SH, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007; 4:e269. This study showed that treatment of LPS-induced ALI with MSCs transfected with a vasculoprotective gene showed further improvement in alveolar inflammation, compared to MSCs alone, suggesting a role for cell-based gene therapy.
62. Wang XX, Zhang FR, Shang YP, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007; 49:1566-1571. This randomized trial showed that intravenous infusion of EPCs may have beneficial effects in patients with IPAH, without any adverse events.